Big Red M Acquires LLM Publications, Expanding Its Suite of Association Services
With the addition of LLM Publications, Big Red M now offers an expanded range of publishing services, including digital and print publications, advertising and design, and distribution solutions. This acquisition positions Big Red M as a one-stop solution for associations seeking to boost their visibility, engagement, and revenue.
"We are thrilled to join forces with Big Red M," said
"Our combined expertise and resources will provide our clients with unparalleled service and innovative solutions. This partnership opens new doors for growth and success, and I am excited about the future for this company."
The acquisition underscores Big Red M's dedication to providing comprehensive and innovative solutions to associations. Clients can expect seamless integration of services, continued high-quality support, and access to a wider array of resources designed to meet their evolving needs.
For more information about Big Red M and its expanded services, please visit https://bigredm.com.
About Big Red M: Big Red M is a premier association growth partner specializing in driving significant revenue increases for associations through targeted membership strategies, sponsorship, sales, research, and consulting. With the recent acquisition of LLM Publications, Big Red M now offers a comprehensive suite of publishing services, further solidifying its position as an industry leader.
Subscribe to our newsletter
Facebook | LinkedIn | Twitter | Instagram
View original content to download multimedia:https://www.prnewswire.com/news-releases/big-red-m-acquires-llm-publications-expanding-its-suite-of-association-services-302178305.html
SOURCE Big Red M
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Phoenix Scholar issue examining AI, institutional trust and the future of work published by University of Phoenix College of Doctoral Studies
- First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
- LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share